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Persons with multiple sclerosis (MS) are less physically active than nondiseased persons and often report low self-efficacy levels. In
the context of an awareness project to promote physical activity and participation in MS, we addressed the impact of training for
and participation in a unique expedition. Medical events, relapses, and self-reported neurological worsening were followed from 6
months before andup to 4months afterwards.Validated patient-reported outcomemeasureswere used to assess fatigue, self-efficacy
in exercising, walking abilities, and illness perception. Nine participants completed the training, expedition, and observational
study. Minor events, relapses, and/or neurological worsening were reported in six participants. The three participants with mild
disability and no cardiovascular risk factors or comorbidities were free of medical and neurological events. We found a significant
reduction ofmotor fatigue at last when compared with the first assessment.The reduction tended to bemore evident in participants
with mild disability (Expanded Disability Status Scale (EDSS) < 4 at baseline). Cognitive fatigue, self-efficacy, and self-reported
walking abilities did not change significantly. Illness perceptions tended to be reduced over time in the domains of consequences,
identity, and concerns. Overall, no major adverse events occurred.
1. Introduction
The benefits of physical activity for overall health have
been extensively documented. Personswithmultiple sclerosis
(MS), even when having limited neurological disability,
appear to be less physically active when compared to age-
matched controls [1].
Therefore, they may lack, at least partially, the positive
effects of physical activity on general health and MS-related
changes in body structure, body functions, activities, and
participation [2]. The beneficial effect of exercise training on
walkingmobility among individuals withMS has been exten-
sively documented [3] and the evidence of improvements
in quality of life and fatigue is supportive [2, 4]. Although
the underlyingmechanisms remain to be elucidated, vascular
comorbidities have been associated with an increased risk of
disability progression in MS [5]. Taken together, increasing
physical activity levels in MS may be important to reduce
morbidity and disability progression.
Unfortunately, the barriers to be physically active are
multiple and include illness perceptions that exercise might
facilitate MS relapses [6]. Meanwhile, it has been shown
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that intensive physical exercise does not lead to increased
relapse rate [7]. Other barriers relate to the perception that
exercise is fatiguing [6]. Fatigue, one of the most prevalent
MS symptoms, occurs in up to 80% of persons with MS
and is the most disabling symptom in many of them. No
consensus on the relationship between fatigue and disease-
related variables has been reached [8]. A link with depression
and anxiety has been suggested [9]. Motivational aspects
might also be implicated [10] and reward responsiveness [11]
has been suggested. Reduced self-efficacy for exercise and
lack of appropriate infrastructure were equally perceived as
barriers by persons with MS living in the community [6]. In
view of the multiplicity of barriers, professional guidance has
been proposed to motivate and support persons with MS to
be physically active [12].
In the context of an awareness project to promote physical
activity and participation in MS, PvA initialized an Andes
trekking for 10 personswithMS,withMachu Picchu (Peru) as
final destination, http://www.msmachupicchu2012.be/. The
opportunity of providing professional coaching and medical
support during training, travelling, and expedition was taken
to prospectively collect data on disease activity, fatigue, illness
perception, walking abilities, and self-efficacy for exercise
during a 10-month period.
2. Methods
2.1. Participants. Ten candidates were recruited by neurolo-
gists and physiotherapists affiliated with the MS Center in
Melsbroek and the fitness center “Fit up” inKontich, Belgium.
Only patients with a mild or moderate degree of neurological
disability due to MS and a high potential of motivation were
considered. After the firstmeeting inMarch 2012, onewoman
decided not to continue. Among other reasons, she did not
want to have her diagnosis to be known in the public domain.
Nine accompanying persons with a medical or physio-
therapeutic background were also involved from the start: 3
physiotherapists, 1 exercise physiologist, 2 coaches, 1 general
physician, 1 neurologist, and 1 medical student.
2.2. Study Protocol. The study protocol was approved by the
leading ethical committee of the University Hospital Leuven
and the local ethical committee of theMS Center, Melsbroek,
Belgium.
Longitudinal data were collected on medical and MS
variables, fatigue, self-efficacy, walking disability, and illness
perception. An overview of the timeline and assessments is
given in Figure 1.
At the firstmeeting, defined as time point 0 (𝑇0, 6months
prior to the expedition) demographic, medical, and MS
variables were collected, including the Expanded Disability
Status Scale (EDSS) [13], assessed by the treating neurologist.
Self-reported medical events, relapses and disability, fatigue,
walking ability, and self-efficacy for exercise were registered
every 2 months resulting in 5 assessments: 1 at the start of
the training (𝑇1), 2 during the training period (𝑇2, 𝑇3), and
2 following the expedition (𝑇4, 𝑇5). Illness perceptions were
assessed at 3 time points (𝑇0, 𝑇1, and 𝑇5). Nine participants
signed the informed consent.
2.3. Outcome Measures. We used the self-assessment scale
of disability developed for the European study on costs
and quality of life in MS [14, 15], which is based on the
original validated description in the Expanded Disability
Status Scale (EDSS) [13] and on the Patient Determined
Disease Steps instrument (PDDS) [16]. Subjects are asked
to select from a series of statements describing limitations
and walking disability. The self-assessment scale of disability
allows participants to be categorized into 11 steps of disability,
from 0 to 10, corresponding to EDDS scores [15].
The “Fatigue Scale Motor Cognition” (FSMC) [17] was
used to assess MS-related cognitive and motor fatigue in MS
in 20 items. This highly sensitive and specific scale has ade-
quate reliability and validity. Cut-off values for the composite
score and the cognitive andmotor components allow patients
to be classified as mildly, moderately, or severely fatigued.
The “MS walking ability scale” (MSWS 12) [18, 19], a
reliable and valid patient-reported measure, assesses the
impact of MS on walking ability. The “Exercise Self–Efficacy
Scale” (ESES) [20] is a 10-item questionnaire that uses a 4-
point Likert’s scoring system. Higher scores are indicative of
higher perceived exercise self-efficacy. The ESES is reported
to be reliable and valid in patients with spinal cord injury [20]
and has been used previously in MS patients [6, 21].
The brief version of the Illness Perception Questionnaire
(IPQ) [22] assesses the beliefs that individuals construct
about their disease. Five items assess cognitive illness rep-
resentations, 2 items assess emotional representations, and
1 item assesses illness comprehensibility. A sum score can
be calculated. The scale has a good test-retest reliability and
concurrent validity with relevant measures [22].
To improve our understanding of how participants expe-
rienced this expedition, a questionnaire was developed.
Potential changes in thoughts, illness beliefs, and self-esteem
were asked, as well as the contributing factors and messages
for the MS community.
Results were analyzed descriptively given the small sam-
ple size. For some analyses, a distinction was made between
persons with EDSS 4 at baseline compared to those with a
lower score. Data were also analyzed using a nonparametric
test. We used the Wilcoxon signed-rank test because mea-
surements of continuous dependent variables were available.
We compared between different time points before and after
the intervention for the group.
2.4. Exercise Test and Training Period. Five months prior to
the expedition, subjects performed a maximal graded exer-
cise test on an electronically braked cycle ergometer (eBike
Basic, General Electric GmbH, Bitz, Germany). Ventilatory
parameters and heart rate were continuously monitored by
a 12-lead ECG device (Jaeger Oxycon, Erich Jaeger GmbH,
Germany). Following a 10min warm-up at 40W, subjects
were seated on cycle ergometer for three minutes to obtain
resting data. Next, subjects were instructed to cycle at a rate
of minimum 70 rpm, against a starting workload of 40W.
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Figure 1: Enrolment, timeline, and assessments at different time points.
Hereafter, workloads were increased every 3min by 40W (D)
and 30W (C) until voluntary exhaustion. Just before work-
loads were increased, heart rate was registered, and capillary
blood lactate (Accutrend Plus, Roche Diagnostics Limited,
Sussex, UK), oxygen uptake, and respiratory exchange ratio
were measured.
Based on the results, a personalized training schedule was
provided in May 2012 (𝑇1). Group meetings were planned to
evaluate walking capacities and training progression of the
participants.
Themaximal graded exercise test A was repeated 6 weeks
after the expedition.
2.5. Salkantay Expedition. On September 20, 2012, the group
flew from Brussels, Belgium, to Lima, Peru. A flight to
Arequipa (2,300m) and a trip to the Colca Canyon valley,
getting over 4,900m, introduced altitude experience. The
flight to Cusco (3,400m) and a bus trip on September 27
brought the group to the start of the 5-day Salkantay trekking.
The estimated altitude at start, altitude meters, walking time,
and distance are given in Table 1 (data obtained by Garmin
GPS).
Walking was also measured by accelerometer (Actibelt,
Sylvia Lawry Center, Munich, Germany). The performance
of participants was monitored by heart rate measurements
(POLAR) and regular self-reported rating of walking ability
and energy levels, to adapt walking pace and rest breaks when
necessary. Horse assistancewas providedwhen necessary and
feasible (steepness) during the first 3 days. Because the effort
was estimated to be too strenuous, parts of the trail during the
last 3 days have been done by bus.
3. Results
3.1. Participants. Baseline characteristics of the nine partic-
ipants with relapsing MS are found in Table 2. The three
participants with EDSS 4 presented with cardiovascular risk
factors (two with smoking and one with obesity).
Training schedules started from low levels in 3 (group 3),
from intermediate levels in 4 (group 2), and from high levels
in 2 participants (group 1). Each group contained one male
representative.
3.2. Clinical Observations. During run-in (𝑇0-𝑇1), one sub-
ject was treated with steroids for a relapse. Two other subjects
developed a relapse during the training phase (𝑇1−−𝑇3). One
of them was treated with pulse steroids. Another subject was
treated with antibiotics because of a bronchial infection.
During travelling, one patient developed gastroenteritis
in Arequipa (Peru). Another patient experienced increased
fatigue and dizziness after having crossed high altitudes
(>4000m). Most subjects got some experience with altitude
sickness at altitudes of 3600m or more. Treatment with
analgesics was given if needed. During the 5-day trekking,
transient sensory complaints were mentioned and increased
equilibrium disturbances were observed in several partici-
pants, without evidence for a relapse. Walking measurement
by accelerometer revealed, across 5 days, an average step
count of 17409 with an average daily step ratio of 94, 8%
between start and end.
In the months following the expedition, four patients
reported increased neurological symptoms, suggestive of
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Table 1: Description of the Salkantay expedition.
Starting point Reference during walking Altitude at start Walking time Distance (km)
Day 1 Mollepata West of Rio Blanco 3348m >6 hours 13.0
Day 2 Soraypampa Across the Salkantay pass, 4600m 3920m >8 hours 16.0
Day 3 Inca campsite Huayramachay Across Rio Santa Teresa 3288m 3 hours 4.4
Day 4 Hydroelectrica Train station Rio Urubamba 1880m 4 hours 9.0
Day 5 Aguas Calientes Machu Picchu 1960m 3 hours 3.1
Table 2: Baseline characteristics of the participants (𝑛 = 9).
Female number (%) 6 (66%)
Relapsing onset (%) 9 (100%)
Age at trekking, year
Median (range) 42 (28–49)
Age at onset of MS, year
Median (range) 30 (23–40)
Disease duration, year
Median (range) 9 (3–24)
EDSS
Median (range) 3 (1–4)
Annualized relapse rate 0.80
Current treatment
Interferon beta or glatiramer acetate 3 (2M 1F)
Natalizumab or alemtuzumab 2 (2F)
No immunomodulatory treatment 4 (1M 3F)
Comorbidity (rheumatoid arthritis, narcolepsy) 2 (2F)
Cardiovascular risk factors (smoking, obesity)∗ 4/9 (2M, 2F)
∗Three of them had reached EDSS 4.
a relapse. For two subjects, this was the second episode. One
of them was treated with pulse steroids at the two occasions.
3.3. Exercise Capacity. Compared to PRE, heart rate at 40W
(PRE: 117 ± 14 b/m versus POST: 108 ± 12 b/m, 𝑃 = 0.09) and
at the aerobic threshold (PRE: 137 ± 8 b/m versus POST: 141 ±
9 b/m, 𝑃 = 0.08) tended to be, respectively, lower and higher
following the training and expedition period. Furthermore,
POSTworkloads at the anaerobic threshold (PRE: 123 ± 43W
versus POST: 132 ± 41W, 𝑃 < 0.05) were lower and peak
blood lactate concentrations were higher after the training
and expedition period (PRE: 8.44 ± 1.0mmol/L versus POST:
9.6 ± 1.3mmol/L, 𝑃 < 0.05).
3.4. Outcome Measures
3.4.1. Self-Assessment Scale of Disability. Although fluctu-
ations in self-reported disease steps were observed in all
subjects, only the three participants with EDSS 4 at baseline
reported a sustained increase. In two of them, this increase
followed a very low, self-assessed disease step at baseline (0
or 1). No further worsening was reported after 𝑇3.
3.4.2. Fatigue. Overall, median values of the FSMC sum
transiently declined (Table 3).
When using the Wilcoxon signed-rank test to compare
fatigue scores at the different time points, a statistically
significant difference was obtained for motor fatigue when
comparing 𝑇1 and 𝑇5 (𝑃 = 0.007). Median values for motor
fatigue appeared to be reduced persistently in participants
with mild disability (EDSS < 4).
Longitudinal data of the number of patients with their
graded fatigue for the sum, cognitive, and motor subscale
of the FSMC are shown in Figure 2. When compared
with baseline, fewer participants reported severe MS-related
fatigue just before the expedition (𝑇3).
3.4.3. Walking Ability and Self-Efficacy for Exercise. Overall,
self-reported walking abilities and self-efficacy for exercise
did not change significantly over time. However, the higher
median values of theMSWS 12 in participants with EDSS 4 at
baseline tended to decline transiently.
3.4.4. Cognitive Illness Representations. Median values with
interquartile ranges are presented in Table 4. A graphical
presentation of the median values is shown in Figure 3.There
were no significant differences when using the Wilcoxon
signed-rank test.
3.4.5. Questionnaire. Participants described this expedition
as heavy, both physically asmentally.Motivation and training
were thought to be essential. Several subjects reported a less
dominant perception of MS as they expressed having a life
with MS, to make their own decisions and get respect from
family and friends. Although most participants reported
feeling stronger, some of them also expressed the hard
confrontation with limitations due to MS. The experience
of wellbeing when being physically active, the support from
family, friends, and MS community, and professional coach-
ing were experienced as very helpful and encouraging. The
messages to other people with MS included advices to be
physically active, to be open for new experiences, and to never
give up.
4. Discussion
In the context of an awareness project to promote physical
activity and participation in MS, we obtained prospective
information on medical and disease variables, fatigue, illness
perception, walking abilities, and self-efficacy for exercise
from6months before and up to 4months after the expedition
in the 9 selected candidates. Three minor medical events (3
subjects), 7 relapses (5 subjects), and sustained neurological
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Table 3: FSMC, ESES, MSWS 12, and brief IPQ, median values (range) and stratified by EDSS 4.
T1 T2 T3 T4 T5
FSMC sum
ALL (𝑛 = 9) 68 (23–79) 59 (29–79) 61 (24–79) 59 (27–82) 69 (26–84)
EDSS < 4 (𝑛 = 6) 68 (23–79) 64 (29–79) 61 (24–79) 62 (27–77) 61 (26–77)
EDSS = 4 (𝑛 = 3) 61 (34–68) 59 (48–72) 58 (38–76) 59 (40–82) 69 (48–84)
FSMC motor
ALL (𝑛 = 9) 31 (10–36) 26 (10–37) 28 (10–37) 28 (13–40) 28 (10–40)
EDSS < 4 (𝑛 = 6) 30.5 (10–36) 26 (10–33) 25.5 (10–30) 26.5 (13–30) 26 (10–30)
EDSS = 4 (𝑛 = 3) 32 (14–33) 32 (25–37) 29 (18–37) 33 (18–40) 35 (22–40)
FSMC cognitive
ALL (𝑛 = 9) 32 (12–47) 33 (19–47) 31 (14–49) 29 (14–47) 34 (16–48)
EDSS < 4 (𝑛 = 6) 35 (12–47) 36 (19–47) 32 (14–49) 34 (14–47) 35 (16–48)
EDSS = 4 (𝑛 = 3) 29 (20–35) 27 (27–35) 29 (20–39) 26 (22–42) 34 (26–44)
MSWS
ALL (𝑛 = 9) 14 (12–39) 13 (12–33) 13 (12–26) 13 (12–31) 14 (12–38)
EDSS < 4 (𝑛 = 6) 13 (12–18) 12.5 (12–15) 12.5 (12–15) 12.5 (12–15) 12 (12–15)
EDSS = 4 (𝑛 = 3) 30 (18–30) 21 (16–33) 23 (13–26) 25 (16–31) 31 (17–38)
ESES
ALL (𝑛 = 9) 36 (27–40) 37 (34–40) 37 (33–40) 37 (33–40) 37 (28–39)
EDSS < 4 (𝑛 = 6) 36 (32–40) 36.5 (34–39) 37 (34–40) 37 (35–39) 37 (35–38)
EDSS = 4 (𝑛 = 3) 37 (27–40) 37 (36–40) 35 (33–40) 35 (33–40) 29 (28–39)
Table 4: Brief IPQ median values (interquartile range).
T0 T1 T5
Overall 49 (40–51) 43 (34–50) 43 (35–51)
Consequences 5 (3–7) 5 (3–7) 3 (3–5)
Timeline 10 (10-10) 10 (10-10) 10 (10-10)
Personal control 6 (4–7) 6 (5-6) 5 (4–7)
Treatment control 7 (6–8) 7 (6–8) 7 (6–8)
Identity 4 (3–5) 3 (2–5) 2 (2–4)
Concern 5 (3–6) 5 (4-5) 3 (2–6)
Understanding 8 (7–9) 7 (6–9) 7 (7-8)
Emotional response 3 (2–6) 2 (2–4) 2 (1–8)
worsening (3 subjects) were reported in six participants.
We found a significant reduction of motor fatigue at the
last assessment (𝑇5) when compared with the first (𝑇1).
When stratifying the results based on the degree of disability
(having reached EDSS 4 or not), the persistence of motor
fatigue tended to be more evident in participants with mild
disability. Cognitive fatigue, self-efficacy, and self-reported
walking abilities did not change significantly. The perceived
illness consequences, identity, and concerns appeared to be
declined over time.
The relapse rate during the observational study period did
not markedly differ from the relapse rate in the year before.
Three of the five participants treated with immunomodula-
tory drugs developed relapses. Steroids were given for 2 of
the 3 MS relapses before and for 1 of the 4 relapses after the
expedition.The three subjects with self-reported neurological
worsening at 𝑇3 had reached EDSS 4 at baseline. Because
they reported no further worsening at later time points, their
estimation at 𝑇3 may have been more realistic than initially.
Remarkably, the three participants, with no cardiovascular
risk factors or comorbidities and mild disability at baseline,
were event-free.
Although we have not measured physical activity in the
community, the tentative changes in exercise tests before and
after the expedition support a training effect. During the
trekking, the efforts by participants, as based on heart rate
monitoring and step counts, corresponded to highly active
walking when compared to habitual community walking
[23].
The observation of reduced fatigue in association with
training is in line with previous findings [2]. A recent
systematic review of interventional studies concluded that
physical exercise has the potential to reduce fatigue inMS [4].
However, findings were heterogeneous and only a few studies
have evaluated fatigue as the primary outcome measure. The
FSMC scale is a new scale [17] and is able to consistently
distinguish between motor and cognitive components of
fatigue in MS. Even though both fatigue components are
not completely independent, increased physical activity for
several months is a strong candidate to reduce motor fatigue.
However, longitudinal data are limited. A treatment effect of
natalizumab has been reported over 12 months, with parallel
declining scores for motor and cognitive fatigue components
[24].
Our findings suggest differences in the pattern of changes
in motor versus cognitive fatigue in relation to training and
disability. The reduction of motor fatigue appeared to be
more evident in mildly disabled patients whereas the severity
of cognitive fatigue remained rather stable over time in all
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Figure 2: Longitudinal data of the number of patients with their graded fatigue for the sum, cognitive and motor subscales of the FSMC.
The timeline of the 5 assessments is presented in the X axis. The percentage of participants is presented in the Y-axis. Different colours are
indicating the severity, based on cut-off values, as indicated. The number of severely fatigued participants changed over time, especially for
the motor subscale. Four subjects started with severe motor fatigue, including 2 subjects with EDSS 4 (𝑇1). A transient reduction occurred
in 3 of them, just before travelling to Peru (𝑇3). Severe motor fatigue came back in 1 subject, which results in 2 subjects with severe motor
fatigue (𝑇5), both with EDSS 4 at baseline.
participants. This has not been reported previously. Because
of the correlations of the motor fatigue subscale with EDSS
[10] and the start of the progressive phase ofMS around EDSS
4, changes in subjects with moderate disability may be more
difficult to obtain and to maintain.
The role of motivation, participation, professional coach-
ing, social support, illness beliefs, reduced anxiety and
depression, or a combination of these factors may also have
played a role in reducing fatigue before and/or increasing
fatigue after the expedition.As stated in the systematic review,
the social interaction component, present in many positive
studies, may affect the perception of fatigue [4]. Participants
in our study not only increased their levels of physical activity
but also played an ambassador role in informing the MS
community.
Overall, there were no longitudinal changes in the
MSWS-12 and the SES for exercise. However, in the sub-
group of subjects with higher disability, the MSWS-12 scores
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Figure 3: Graphical representation of longitudinal data on IPQ
items. The timeline of the 3 assessments is presented in the 𝑋-
axis. The median values for each item are presented in the 𝑌-axis.
Different colours are indicating the items. Item 1 (consequences)
coincides with item 6 (concern). A reduction of 2 points is observed
for the items 1 and 5 (consequences and identity), assessing cognitive
illness representations.The item “illness identity” is ameasure of the
signs and symptomsperceived by the person to be part of the disease.
The item “illness consequences” refers to the perceived effects and
outcomes of illness. The median values of this item coincide with
those of item 6 (concern). The item “concern” (item 6) assesses
emotional representations.
transiently tended to decline before returning to baseline
levels at the final assessment. The validation of the MSWS-
12 in MS patients with, on average, a substantial mobility
limitation suggests that the sensitivity to detect changes in
mild MS may be limited [18, 25]. Instead of changes in
perceived walking ability, they may have changed overall
physical activity levels reflecting habitual performance. The
overall high scores on the SES were indicative of a high self-
efficacy for exercise. This probably reflects coping behaviour
with regard to exercise. The belief in one’s capabilities to
take the necessary actions required for adhering to exercise
has been strongly associated with physical activity in a
recent longitudinal study of individuals with MS [26]. The
significance of the final decline in self-efficacy in subjectswith
moderate disability remains to be determined.
The assessments of cognitive and emotional representa-
tions of illness suggest a reduction in the perceived adverse
consequences, the signs and symptoms perceived to be part
of MS (identity), and the expression of concerns. Together
with the message for the MS community to be open for
new experiences, expressed by several participants, our data
suggest a less dominant and less negative perception of MS.
When diagnosed with MS, uncertainty and potential
functional loss are leading to overall anxiety and threatening
health-related quality of life. In an attempt to make sense
of this illness experience, individuals construct cognitive
models about MS. These beliefs are thought to be important
for determining an individual’s response [27], which is then
appraised for efficacy. Evidence suggests that illness represen-
tations relate to later outcomes in several conditions [28–30].
While cross-sectional studies have reported associations with
health-related quality of life, adjustment, depression, self-
esteem, and activities of daily life [27, 30, 31], no longitudinal
data have been published in MS. Interventions addressing
negative illness cognitions may potentially improve health-
related outcomes. In the context of our study, participation
and professional guidance of persons with MS including
information, motivation, and support may have contributed
to changing these beliefs.
We fully acknowledge the limitations of this exploratory
study. First, the number of participants is limited. Second,
individuals were selected on motivation and disability, given
that this was the first expedition that focused on feasibility
rather than proposing a standard intervention for all. We
cannot generalize our findings to persons with MS with
severe disability, even thoughwe aim to encourage all persons
with MS to be physically active and to participate in the
community with an active lifestyle. Third, the intervention
included but was not limited to physical training. In the
absence of a control group, we cannot exclude random or
time-dependent changes in the severity of MS-related fatigue
or illness perceptions. Fourth, the small sample did not allow
us to look for interaction effects in participants with mild
and moderate disability (𝑛 = 2 only). Fifth, the occurrence
of medical events, relapses, and neurological worsening was
primarily based on judgement by the participant. Neverthe-
less, confirmation by the treating physician was asked and
information about MS diagnosis, comorbidities, and EDSS
was obtained from the treating neurologist.
5. Conclusions
This 10-month observational study allows concluding that
physical training and participation to a unique expedition has
been feasible for the selected individuals with MS. Overall,
minor events were observed in two thirds of the participants.
All of them either hadmoderate disability, cardiovascular risk
factors, and/or comorbidities at baseline. Motor fatigue was
significantly reduced. This effect tended to be more evident
in participants with mild disability.
Illness beliefs tended to be reduced including a less
dominant perception of MS.
Further studies in MS are needed to address the role
of disability, disease stage, cardiovascular risk factors, and
comorbidities in training and the severity of fatigue. Distin-
guishing motor and cognitive fatigue and assessing illness
perceptions may help to clarify the underlying mechanisms
of MS-related fatigue.
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